Natixis Advisors LLC Has $4.75 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Natixis Advisors LLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 27.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,287 shares of the company's stock after acquiring an additional 3,042 shares during the period. Natixis Advisors LLC's holdings in Medpace were worth $4,747,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Centaurus Financial Inc. grew its stake in Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock valued at $505,000 after purchasing an additional 29 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares during the last quarter. HBK Sorce Advisory LLC boosted its holdings in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock valued at $1,789,000 after buying an additional 29 shares during the last quarter. Assetmark Inc. grew its stake in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares in the last quarter. Finally, Proficio Capital Partners LLC increased its holdings in Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Remove Ads

Medpace Stock Performance

NASDAQ:MEDP traded down $6.86 during mid-day trading on Wednesday, hitting $317.65. 549,067 shares of the stock were exchanged, compared to its average volume of 290,505. The firm's 50-day simple moving average is $337.16 and its 200 day simple moving average is $339.57. The stock has a market capitalization of $9.68 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on MEDP shares. Robert W. Baird lifted their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday. Finally, Leerink Partners initiated coverage on Medpace in a research note on Monday. They issued a "market perform" rating and a $330.00 price objective on the stock. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $376.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.